P4 Diagnostix has teamed with Pierian, a company that provides an analysis platform, to launch somatic testing for patients with prostate cancer. The partnership will further develop P4 Diagnostix’s ...
Panel testing for genetic variants linked to more cancers is cost-effective than just testing or BRCA1/2 mutations, says a clinical director for a women's health company. If caught early, the survival ...
We conducted a retrospective database analysis using medical and pharmacy claims data. Medicare Advantage Prescription Drug Plan members diagnosed with select malignant solid tumors were identified.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results